Filtros de búsqueda

Lista de obras de

A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies

artículo científico publicado en 2020

A model-based economic evaluation of four newborn screening strategies for cystic fibrosis in Flanders, Belgium

artículo científico publicado en 2019

A review of the value of innovation in inhalers for COPD and asthma.

artículo científico publicado en 2015

A systematic review on costs and cost-effectiveness of screening and prevention of type 2 diabetes in women with prior gestational diabetes: Exploring uncharted territory

artículo científico publicado en 2018

Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation

artículo científico publicado en 2017

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel

artículo científico publicado en 2017

Analysis of French generic medicines retail market: why the use of generic medicines is limited.

artículo científico

Analysis of Spanish generic medicines retail market: recommendations to enhance long-term sustainability.

artículo científico publicado en 2014

Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability

artículo científico publicado en 2014

Appropriateness of Acid Suppression Therapy.

artículo científico publicado en 2016

Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis.

artículo científico publicado en 2017

Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets

artículo científico publicado en 2018

Barriers to the uptake of biosimilars and possible solutions: a Belgian case study.

artículo científico

Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets

artículo científico publicado en 2020

Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications

artículo científico publicado en 2014

Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group

article

Clinical, Economic and Policy Implications of Drug Shortages in the European Union.

artículo científico publicado en 2016

Collaborative approach to Optimise MEdication use for Older people in Nursing homes (COME-ON): study protocol of a cluster controlled trial

artículo científico publicado en 2016

Correction to: The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

scientific article published on 02 June 2020

Cost Effectiveness of Lacosamide in the Adjunctive Treatment of Patients with Refractory Focal Epilepsy in Belgium

artículo científico publicado el 1 de abril de 2012

Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer

artículo científico publicado en 2017

Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting

artículo científico publicado en 2013

Cost-utility analysis of lifestyle interventions to prevent type 2 diabetes in women with prior gestational diabetes

scientific article published on 30 October 2019

Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.

artículo científico publicado en 2013

Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study

scientific article published on 03 December 2019

Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement.

artículo científico publicado en 2016

Development and implementation of "Check of Medication Appropriateness" (CMA): advanced pharmacotherapy-related clinical rules to support medication surveillance

artículo científico publicado en 2019

Development and validation of COMPASS: clinical evidence of orphan medicinal products - an assessment tool

artículo científico publicado en 2013

Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting.

artículo científico publicado en 2019

Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient Setting.

artículo científico publicado en 2019

Do we need authorized orphan drugs when compounded medications are available? ⬇️

artículo científico publicado el 14 de septiembre de 2012

Does increased use of generic medicines by elders in Belgium help to contain escalating health care budgets?

artículo científico publicado en 2014

Economic evaluation of biosimilars for reimbursement purposes - what, when, how?

scientific article published on 15 March 2020

Ethical, legal and social implications of rare diseases and orphan drugs in Europe: meeting report of a Brocher symposium

artículo científico publicado en 2013

European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption

artículo científico publicado en 2020

European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice

artículo científico publicado en 2020

European drug shortages: a call for action! ⬇️

artículo científico publicado el 1 de febrero de 2013

Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US

scientific article published on 18 September 2019

Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review

artículo científico publicado en 2018

Financial based agreements and performance based agreements: the Belgian experience.

artículo científico publicado en 2015

Health technologies for rare diseases: does conventional HTA still apply?

article

Health-care use drives the economic burden of blood disorders in Europe.

artículo científico publicado en 2016

Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!

artículo científico publicado en 2020

Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders

artículo científico publicado en 2014

Integrative Review of Managed Entry Agreements: Chances and Limitations

artículo científico publicado en 2020

Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future

artículo científico publicado en 2016

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany

artículo científico publicado en 2020

Length of stay after reaching clinical stability drives hospital costs associated with adult community-acquired pneumonia ⬇️

artículo científico publicado el 31 de octubre de 2012

Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future

artículo científico publicado en 2017

Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations

artículo científico publicado en 2017

Market access of orphan drugs and the role of multi-criteria decision making.

artículo científico publicado en 2012

Nanomedicines: The magic bullets reaching their target?

scientific article published on 20 November 2018

Off-label use of orphan medicinal products: a Belgian qualitative study.

artículo científico publicado en 2016

Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review

artículo científico publicado en 2019

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies

artículo científico publicado en 2016

Patient Involvement in the Lifecycle of Medicines According to Belgian Stakeholders: The Gap Between Theory and Practice

article

Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA

scientific article published on 01 October 2019

Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways

artículo científico publicado en 2016

Personalizing health care: feasibility and future implications

artículo científico publicado en 2013

Policies for biosimilar uptake in Europe: An overview.

artículo científico publicado en 2017

Preventing COPD exacerbations with macrolides: A review and budget impact analysis ⬇️

artículo científico publicado el 23 de enero de 2013

Preventing COPD exacerbations with macrolides: a review and budget impact analysis--author response to letter to the editor

artículo científico publicado en 2014

Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA

artículo científico publicado en 2019

Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers

artículo científico publicado en 2016

Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries

artículo científico publicado en 2013

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries

scientific article published on 27 November 2019

Reimbursement of orphan drugs in Belgium: what (else) matters?

artículo científico publicado en 2014

Risk-Return Analysis of the Biopharmaceutical Industry as Compared to Other Industries

artículo científico publicado en 2018

Strategies for newborn screening for cystic fibrosis: A systematic review of health economic evaluations

artículo científico publicado en 2018

Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review

artículo científico publicado en 2020

Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries.

artículo científico publicado en 2017

Tendering and biosimilars: what role for value-added services?

artículo científico publicado en 2019

The Evaluation of Economic Methods to Assess the Social Value of Medical Interventions for Ultra-Rare Disorders (URDS).

artículo científico publicado en 2014

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

scientific article published on 01 February 2020

The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape

artículo científico publicado en 2017

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars

scientific article published on 01 July 2019

The insights of health and welfare professionals on hurdles that impede economic evaluations of welfare interventions.

artículo científico publicado en 2017

The necessity for a European definition of drug shortages

scientific article published on 01 August 2018

Time spent by Belgian hospital pharmacists on supply disruptions and drug shortages: An exploratory study

artículo científico publicado en 2017

Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab

scientific article published on 01 February 2020

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease

artículo científico publicado en 2015

Universal Mental Health Interventions for Children and Adolescents: A Systematic Review of Health Economic Evaluations

artículo científico publicado en 2020

What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population

artículo científico publicado en 2019

Why "American Patients First" is likely to raise drug prices outside of the United States

artículo científico publicado en 2019

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda